ASLAN Firms Up IPO Plans As Lead Asset Progresses
Executive Summary
Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.
You may also be interested in...
IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?
Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.
ASLAN Refills Pipeline With Homegrown Immuno-Onc Asset
Singapore's ASLAN has signed its second deal in the past few weeks, acquiring global rights to an early stage immuno-oncology molecule that helps to fill a pipeline hole left by a recent out-licensing deal with Bristol-Myers Squibb.
BMS Reacquisition Bulks Up ASLAN’s Deal Chest
Singapore's ASLAN has licensed back to originator BMS the Asian rights to a novel oncology molecule with potential as both a mono and combination therapy, boosting funding for potential future deals in the process.